Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren’s syndrome

ObjectivesThis study aimed to evaluate the efficacy of iguratimod (IGU) and hydroxychloroquine (HCQ) in the treatment of primary Sjögren’s syndrome (pSS).MethodsThis was a randomised controlled study. A total of 60 patients with pSS in Mianyang Central Hospital were recruited between December 2020 a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jin-Mei Zou, Li Yang, Jia-Ang Luo, Yan Ren, Si-Yin Li, Yu Zhang, Jian-Ling Dong, Dai-Hua Deng, Yuan-Piao Ni, Min Li, Xiao-Shuang Yin, Jing Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Medicine
Subjects:	primary Sjögren’s syndrome regulatory B cells iguratimod hydroxychloroquine treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1573973/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren’s syndrome

Similar Items